The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD

BACKGROUND: Navafenterol (AZD8871) belongs to a new class of bronchodilator, the single-molecule muscarinic antagonist and β-agonist, developed for the treatment of COPD. This study aimed to evaluate the efficacy, pharmacokinetics and safety of navafenterol versus placebo and an active comparator tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Dave, Beier, Jutta, Astbury, Carol, Belvisi, Maria G., Da Silva, Carla A., Jauhiainen, Alexandra, Jimenez, Eulalia, Lei, Alejhandra, Necander, Sofia, Smith, Jaclyn A., Wählby Hamrén, Ulrika, Xin, Wenjing, Psallidas, Ioannis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989052/
https://www.ncbi.nlm.nih.gov/pubmed/34503985
http://dx.doi.org/10.1183/13993003.00972-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989052/
https://www.ncbi.nlm.nih.gov/pubmed/34503985
http://dx.doi.org/10.1183/13993003.00972-2021

Ejemplares similares